2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
March 2026 in “JMIR Dermatology” Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.
February 2026 in “Frontiers in Medicine” Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
February 2026 in “Colloids and Surfaces A Physicochemical and Engineering Aspects” JAK inhibitors can enter the skin through hair follicles using a unique pathway.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.
June 2025 in “British Journal of Dermatology” JAK inhibitors help regrow hair in alopecia areata, but their long-term safety is still unclear.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
April 2025 in “International Journal of Dermatology” JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
June 2024 in “Military medicine” JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
January 2024 in “Updates in clinical dermatology” JAK inhibitors, PRP, and exosomes show promise for hair regrowth in Alopecia Areata.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors partially restore scalp bacteria balance in alopecia areata patients.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
January 2023 in “Indian Dermatology Online Journal” No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.